Vanderbilt-Ingram Cancer Center

Vanderbilt-Ingram website >

Eunyoung Choi, PhD
April 5, 2024

Eunyoung Choi’s gastric cancer research merits AACR-Debbie’s Dream funding

Ongoing research by Eunyoung Choi, PhD, into how cells transform into abnormal versions of themselves that are the precursors to stomach cancer has received support from the American Association for Cancer Research.

By Tom Wilemon
(iStock image)
April 3, 2024

Excess salt linked to heart disease deaths in low-income group: study

Excessive consumption of dietary sodium likely was responsible for up to 30% of cardiovascular disease-related deaths among mostly low-income participants in a large cohort study conducted by Vanderbilt University Medical Center.

By Bill Snyder
March 28, 2024

Study identifies molecule as potential target for treating AML

While immune checkpoint inhibitors that target the PD-1 molecule on T-cells have proven to be effective with many cancers, these immunotherapies have not worked for acute myeloid leukemia (AML), but new research has identified a “cousin” molecule as a potential therapeutic target for AML. 

By Tom Wilemon
March 8, 2024

Scalp cooling allows woman to keep hair during chemotherapy

The Food and Drug Administration first granted marketing approval for the DigniCap system for patients with breast cancer in 2015, then in 2017 the FDA expanded the authorization, making it the first cooling cap cleared for use in cancer patients with solid tumors, such as breast cancer, ovarian cancer and colorectal cancer.

By Tom Wilemon
March 5, 2024

GE HealthCare & Vanderbilt publish data on AI models predicting patient response to immunotherapy

The results from a research partnership between GE HealthCare and Vanderbilt University Medical Center utilizing artificial intelligence to enable safer and more precise cancer immunotherapies show that the models they developed predict patient responses with 70% to 80% accuracy.

By Tom Wilemon
January 22, 2024

Molecular profiles of tissue plus circulating tumor DNA can better guide cancer care

Vanderbilt research indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.

By Tom Wilemon